Estrogen Receptor Variants, HDL, and Atherosclerosis

NCT00081705 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2016-07-29

No results posted yet for this study

Summary

To measure the association between estrogen receptor variants and the extent of atherosclerosis in the thoracic and abdominal aorta and the right coronary artery in subjects in the PDAY study.

Conditions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • David Herrington · Wake Forest University Health Sciences

Eligibility

Min Age
15 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00081705 on ClinicalTrials.gov